•  
  •  
 

Subject Area

Dermatology

Article Type

Original Study

Abstract

Objective The aim of this work was to assess the influence of secondary hyperparathyroidism (SHPT) on left ventricular function in end-stage kidney disease in Egyptian patients under maintenance hemodialysis. Background SHPT is a common disorder in patients with chronic kidney disease. Parathyroid hormone (PTH) is a major uremic toxin and may be responsible for long-term consequences that include renal osteodystrophy, severe vascular calcifications, alterations in cardiovascular structure and function, immune dysfunction, and anemia. PTH has been identified as an important cardiotoxin in end-stage kidney disease and may cause deleterious effects in myocardium metabolism and function. Materials and methods A total of 86 end-stage kidney disease patients on maintenance hemodialysis were recruited from the Hemodialysis Unit in the National Institute of Urology and Nephrology in Cairo, Egypt. Patients were divided into two groups: group I – comprised 39 patients with controlled SHPT (PTH: 150–300 pg/ml) and group II comprised 47 patients with uncontrolled SHPT (PTH: ≥350 pg/ml). Results There was no statistically significant difference between the two groups as regards the systolic function and diastolic dysfunction or with respect to the development of left ventricular hypertrophy. On the other hand, there was a statistically significant correlation between uncontrolled SHPT and the development of valvular calcifications of mitral and aortic valves. Conclusion Uncontrolled SHPT in hemodialysis patients is not associated with the development of left ventricular hypertrophy in our studied patients.

Download

Share

COinS